Document Detail


Are analogue insulins superior to human insulin in clinical practice?
MedLine Citation:
PMID:  20425580     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Insulin analogues were designed to provide more physiologic pharmacokinetic and pharmacodynamic properties compared with human insulin. This article examines the literature over a 2-year period, focusing on studies directly comparing analogue and human insulin in controlled clinical trials and large observational studies documenting the introduction of, or change to, analogue insulin in clinical practice. Findings indicate that analogues provide objective benefits that include improved glycemic control, lower risk of hypoglycemia, lower glucose variability, and (for insulin detemir) reduced weight gain. Recent data with analogues also explore their safety and efficacy in special patient groups such as children and adolescents. These data complement increasing evidence that analogues offer improved acceptability and accessibility to people with diabetes.
Authors:
Jeffrey S Freeman
Publication Detail:
Type:  Journal Article; Meta-Analysis    
Journal Detail:
Title:  Current diabetes reports     Volume:  10     ISSN:  1539-0829     ISO Abbreviation:  Curr. Diab. Rep.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-04-28     Completed Date:  2010-09-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101093791     Medline TA:  Curr Diab Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  176-83     Citation Subset:  IM    
Affiliation:
Division of Endocrinology of the Department of Internal Medicine, Division of Endocrinology and Metabolism, Philadelphia College of Osteopathic Medicine, Suite 324, Philadelphia, PA 19131-1626, USA. jeffreyfreemando@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Humans
Insulin / analogs & derivatives*,  pharmacology*
Insulin, Long-Acting / pharmacology
Physician's Practice Patterns*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Insulin, Long-Acting; 11061-68-0/Insulin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Weight management using a meal replacement strategy in type 2 diabetes.
Next Document:  Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus.